ResTORbio's respiratory illness drug fails late-stage study

ResTORbio's respiratory illness drug fails late-stage study
Reuters: Health
ResTORbio Inc's said on Friday its lead drug missed the main goal in a late-stage testing in patients aged above 65 with respiratory illness.